Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tempest Therapeutics, Inc.OVAS · Entity 7734 | Director · Executive Chair | June 21, 2017 | June 24, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tempest Therapeutics, Inc.
Report date June 21, 2017 · Filed June 24, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.46 · Expires 2027-06-21 | Direct | 175,000 |
Reported balance
After 2017-06-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-21 · Grant · Acquired 175,000 · Balance 175,000 F1: (1) 12.5% of the shares underlying the option shall vest on September 21, 2017 and 12.5% of the shares underlying the option shall vest at the end of each successive three-month period thereafter until June 21, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: (1) 12.5% of the shares underlying the option shall vest on September 21, 2017 and 12.5% of the shares underlying the option shall vest at the end of each successive three-month period thereafter until June 21, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 21, 2017 Filed Jun 24, 2017 00:54 UTC | Tempest Therapeutics, Inc. OVAS · Entity 7734 | GrantStock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $1.46 | $0.00 |
DisclosureSEC source: 0001179110-17-009551 · edgar.xml · derivative · entry 1 Dipp Michelle · CIK 0001551614 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2027-06-21 F1 · derivative.exercise_date: (1) 12.5% of the shares underlying the option shall vest on September 21, 2017 and 12.5% of the shares underlying the option shall vest at the end of each successive three-month period thereafter until June 21, 2019. Read SEC document |
| March 02, 2017 Filed Mar 7, 2017 01:07 UTC | Tempest Therapeutics, Inc. OVAS · Entity 7734 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $1.49 | $0.00 |
DisclosureSEC source: 0001179110-17-004066 · edgar.xml · derivative · entry 1 Dipp Michelle · CIK 0001551614 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-03-02 F1 · derivative.exercise_date: The option vests as to 25% of the option shares on March 2, 2018 and vests as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter thereafter until March 2, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.